A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to MK-8591A Once-Daily in participants with HIV-1 Virologically Suppressed on Antiretroviral Therapy (ART).midwayadmin2020-11-03T20:01:11+00:00
A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to MK-8591A Once-Daily in participants with HIV-1 Virologically Suppressed on Antiretroviral Therapy (ART).
MK8591A-017 · Trial ·
Major Inclusion/Exclusion Criteria:
- <50 HIV RNA for greater than 3 months
- CD4 >100
- GFR >30
- No resistance to Doravarine